Nurtec ODT

News

Pfizer offers $60m to settle prescriber kickback claims

Pfizer has paid $60m to settle US government allegations that its Biohaven unit made improper payments to prescribers of its migraine drug Nurtec ODT.

News

Pfizer’s migraine push builds with Zavzpret nod

Zavzpret is first CGRP to be approved in a nasal formulation designed to be rapid acting.

News

AbbVie files Qulipta for chronic migraine prevention

AbbVie has filed for approval of its oral CGRP inhibitor Qulipta for prevention of chronic migraine, seeking to leap ahead of its main rival in the class.

Pfizer offers $60m to settle prescriber kickback claims

Pfizer’s migraine push builds with Zavzpret nod

AbbVie files Qulipta for chronic migraine prevention

AZ seeking $1.5bn in savings by end-2029

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks